Kalbe Farma Tbk PT Market Cap ($1.94 Billion)
Market Cap & Net Worth: Kalbe Farma Tbk PT (KLBF)
Kalbe Farma Tbk PT market cap. Kalbe Farma Tbk PT (JK:KLBF) has a market capitalization of $1.94 Billion (Rp33.03 Trillion) as of November 3, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #6030 globally and #45 in its home market, demonstrating a 1.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kalbe Farma Tbk PT's stock price Rp730.00 by its total outstanding shares 45248860110 (45.25 Billion). Also see Kalbe Farma Tbk PT cash conversion from operations for how efficiently the company converts equity into cash flow.
Kalbe Farma Tbk PT Market Cap History (2015–2026)
Kalbe Farma Tbk PT market cap history from 2015 to 2026. Data shows change from $2.97 Billion to $1.94 Billion (-4.62% CAGR). Check latest Kalbe Farma Tbk PT stock price today for real-time trading data and today's change.
Index Memberships
Kalbe Farma Tbk PT is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
IDX 30 Jakarta
IDX30
|
$161.81 Billion | 1.20% | #21 of 30 |
|
Jakarta Stock Exchange Composite Index
JKSE
|
$412.24 Billion | 0.47% | #45 of 864 |
Weight: Kalbe Farma Tbk PT's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kalbe Farma Tbk PT Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kalbe Farma Tbk PT's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KLBF year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Kalbe Farma Tbk PT's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Kalbe Farma Tbk PT's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.45 Billion | $19.37 Trillion | $2.30 Trillion | 0.00x | 0.00x |
| 2017 | $3.91 Billion | $20.18 Trillion | $2.40 Trillion | 0.00x | 0.00x |
| 2018 | $3.59 Billion | $21.07 Trillion | $2.46 Trillion | 0.00x | 0.00x |
| 2019 | $3.90 Billion | $22.63 Trillion | $2.51 Trillion | 0.00x | 0.00x |
| 2020 | $3.63 Billion | $23.11 Trillion | $2.73 Trillion | 0.00x | 0.00x |
| 2021 | $4.03 Billion | $26.26 Trillion | $3.18 Trillion | 0.00x | 0.00x |
| 2022 | $5.33 Billion | $28.93 Trillion | $3.38 Trillion | 0.00x | 0.00x |
| 2023 | $4.18 Billion | $30.45 Trillion | $2.77 Trillion | 0.00x | 0.00x |
| 2024 | $3.61 Billion | $32.63 Trillion | $3.24 Trillion | 0.00x | 0.00x |
| 2025 | $3.19 Billion | $35.32 Trillion | $3.66 Trillion | 0.00x | 0.00x |
Competitor Companies of KLBF by Market Capitalization
Companies near Kalbe Farma Tbk PT in the global market cap rankings as of November 3, 2026. Also see KLBF total assets for a full breakdown of the balance sheet.
Key companies related to Kalbe Farma Tbk PT by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #13 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #13 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1417.54 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $273.20 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $294.89 |
Market Capitalization of Kalbe Farma Tbk PT (2015–2026)
Market capitalization of Kalbe Farma Tbk PT from 2015 to today. Between 2015 and today, Kalbe Farma Tbk PT's market cap moved from $2.97 Billion to $ 1.94 Billion, with a yearly change of -4.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp1.94 Billion | -39.42% |
| 2025 | Rp3.19 Billion | -11.40% |
| 2024 | Rp3.61 Billion | -13.80% |
| 2023 | Rp4.18 Billion | -21.57% |
| 2022 | Rp5.33 Billion | +32.25% |
| 2021 | Rp4.03 Billion | +11.20% |
| 2020 | Rp3.63 Billion | -6.92% |
| 2019 | Rp3.90 Billion | +8.59% |
| 2018 | Rp3.59 Billion | -8.22% |
| 2017 | Rp3.91 Billion | +13.17% |
| 2016 | Rp3.45 Billion | +16.31% |
| 2015 | Rp2.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Kalbe Farma Tbk PT was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.94 Billion USD |
| MoneyControl | $1.94 Billion USD |
| MarketWatch | $1.94 Billion USD |
| marketcap.company | $1.94 Billion USD |
| Reuters | $1.94 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devi… Read more